Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers ...
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
Tandem’s Control-IQTM hybrid closed-loop technology now integrates with the 15-day continuous glucose monitoring sensor. This ad will auto-close in 10 seconds ...
Abbott, the creator of continuous glucose monitors, launched the new Assist feature at CES 2026. Part of the Libre app, it ...
Abbott has launched Libre Assist, a feature within the Libre app designed to help people living with diabetes better understand how the foods they eat affect their glucose levels.
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc (TNDM). (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with ...
Insulet Corp. received the greenlight from EU regulators to combine its Omnipod 5 automated insulin delivery (AID) system with Abbott Laboratories Freestyle Libre 2 Plus sensor to treat individuals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback